Boron Neutron Capture Therapy Against Tumor Cells with Overexpression of the EGF-Receptor
The binary nature of boron neutron capture therapy, BNCT, is an advantage because the tumor-seeking substance can be activated at any chosen time and because the neutron field can be delivered to selected areas so that exposure of critical healthy organs, which might contain significant amounts of boron, can be avoided. The tumor selective action should work in spite of the fact that tumor cells often have an infiltrative growth pattern being mixed with populations of normal cells. The targeting principle should be based on well-characterized properties of the tumor cells such as appearence of tumor-associated antigens or overexpression of receptors. The targeting agent could be antibodies, antibody-fragments or receptor ligands. Presently, mainly monoclonal antibodies are considered as targeting substances but it has been claimed that current approaches are limited by low uptake in the tumors studied. Thus, it seems necessary to also consider other principles such as growth factor mediated targeting (1–4).
KeywordsGlioma Cell Boron Neutron Capture Therapy Clonogenic Survival Boron Compound Neutron Field
Unable to display preview. Download preview PDF.
- 1.Carlsson, J.; Gedda L, Grönvik C, Hartman T, Lindström A, Lindström P, Lundqvist H, Lövqvist A, Malmqvist J, Olsson P, Essand M, Pontén J, Sjöberg S and Westermark B: Strategy for boron neutron capture therapy against tumor cells with over-expression of the epidermal growth factor-receptor. Int. J. Radiat. Oncol. Biol. Phys. 30 (1): 105–115, 1994.PubMedCrossRefGoogle Scholar
- 3.Blomquist, E.; Carlsson, J. Strategy for planned radiotherapy of malignant gliomas. Postoperative treatments with high dose proton irradiation and tumor seeking radionuclides. Int. J. Rad. One. Biol. Phys. 22: 259–263; 1991.Google Scholar
- 8.Liberman, T. A.; Nusbaum, H, R.; Razon, N.; Kris, R.; Lax, 1.; Soreq, H.; Whittle, N.; Waterfield, M. D.; Schlessinger, J. Amplification, enhanced expression and possible rearragement of EGF receptor gene in primary human brain tumors of glial origin. Nature 313: 144–147; 1985.Google Scholar
- 9.Murphy, L. C.; Dotzlaw, H.; Wong, M. S. J.; Miller, T.; Mroczkowski, B.; Gong, Y.; Murphy, L. J. Epidermal growth factor: receptor and ligand expression in human breast cancer. Seminars in Cancer Biology I (5): 305–316; 1990.Google Scholar
- 10.Ozawa, S.; Ueda, M.; Ando, N.; Abe, O.; Minoshima, S.; Shimzu, N. Selective killing of squamous carcinoma cells by an immunotoxin that recognizes the EGF receptor. Int. J. Cancer 43 (1): 152–157; 1989.Google Scholar
- 15.Sjöberg, S.; Hawthorne, M. F.; Lindström, P.; Malmquist, J.; Carlsson, J.; Andersson, A.; Pettersson, O. Assymetric synthesis of carboranyl amino acids with potential use in BNCT. In “Neutron Capture Therapy”. Editors: Soloway, A. H., Barth R. F. and Carpenter D. E., pp 269–272. Plenum Press, New York, 1993.CrossRefGoogle Scholar
- 19.Olsson, P.; Lindström, A.; Carlsson, J. Internalization and excretion of epidermal growth factor-dextran associated radioactivity in cultured human squamous carcinoma cells. Int. J. Cancer, 56: 529–537; 1994.Google Scholar
- 20.Haigler, H. T.; Maxfield, F. R.; Willingham, M. C.; Pastan, I. Dansylcadaverine inhibits internalization of ‘251-epidermal growth factor in BALB 3T3 cells. J. Biol. Chem. 855: 1239–1241; 1980.Google Scholar
- 22.Scott-Robson, S.; Capala, J.; Carlsson, J.; Malmborg, P.; Lundqvist, H. Distribution and stability in the rat of a 76Br/1251 labelled polypeptide, epidermal growth factor. Int. J. applied Radiation and Isotopes, Nucl. Med. Biol. 18 (2): 241–246; 1991.Google Scholar
- 23.Lindström, A.; Lundqvist, H.; Carlsson, J. Distribution of 125I after administration of 1251-labelled epidermal growth factor-dextran conjugates in mice. Acta Universitatis Upsaliensis, Vol.: 428: chapter 5; 1993.Google Scholar